Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
28
28 articles ont été cités au moins 28fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
5 525
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
109
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
43
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Virchow-Villermé · Université de Rouen Normandie
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
2024ArticleJournal of Clinical Oncology
PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
2024ArticleHaematologica
Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC
2023Congrès65th ASH Meeting
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock
2023ArticleClinical Nutrition ESPEN
Germline JAK2 E846D Substitution as the Cause of Erythrocytosis?
2023ArticleGenes
On behalf of the SFGM-TC: prophylactic donor lymphocyte infusion in patients treated with allogeneic stem-cell transplantation for high-risk myelodysplastic syndrome and acute myeloid leukemia.
2023ArticleActa Haematologica
Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas
2021ArticleHaematologica
Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Société Francophone de Greffe de Moelle et de Therapie Cellulaire
2021ArticleBone Marrow Transplantation
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CLCC H BECQUEREL
LE CANCER R D'AMIENS CS 11516, 76038 ROUEN CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Lancet (London, England) · 2012
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010
PurposeIn patients with acute myeloid leukemia (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine. High doses of cytarabine have been reported as being too toxic for patients older than age 50 years, but few studies have evaluated intensified doses of anthracyclines.Patients and MethodsIn this randomized Acute Leukemia French Association 9801 (ALFA-9801) study, high doses of daunorubicin (DNR; 80 mg/m2/d × 3 days) or idarubicin (IDA4; 12 mg/m2/d × 4 days) were compared with standard doses of idarubicin (IDA3; 12 mg/m2/d × 3 days) for remission induction in patients age 50 to 70 years, with an event-free survival (EFS) end point. After two consolidation courses based on intermediate doses of cytarabine, patients in continuous remission were randomly assigned to receive or not receive maintenance therapy with recombinant interleukin-2 (rIL-2; 5 × 106U/m2× 5 days each month) for a total duration of 12 months. A total of 468 patients entered the study (median age, 60 years).ResultsOverall complete remission rate was 77% with significant differences among the three randomization arms (83%, 78%, and 70% in the IDA3, IDA4, and DNR arms, respectively; P = .04). However, no significant differences were observed in relapse incidence, EFS, or overall survival among the three arms. In the 161 patients randomly assigned for maintenance therapy, no difference in outcome was observed between the rIL-2 and the no further treatment arms.ConclusionNeither intensification of anthracycline doses nor maintenance with rIL-2 showed a significant impact on AML course, at least as scheduled in this trial.
European journal of haematology · 2014
AbstractObjectivesApproximately 30% of DLBCL patients are older than 70 yr. This study evaluated the prognostic impact of a cachexia score (CS) including fat tissue loss (adipopenia) and sarcopenia as assessed by computed tomography (CT scan) in elderly DLBCL patients treated with chemotherapy and rituximab (R).MethodsThis retrospective analysis included 80 DLBCL patients older than 70 yr treated with R‐CHOP or R‐miniCHOP. Skeletal muscle (SM) and visceral (V) and subcutaneous (S) adipose (A) tissues were measured by analysing CT images at the third lumbar (L3) level.ResultsThe median age of the patients was 78 yr. Forty‐four and 46 patients were considered sarcopenic and adipopenic, respectively. The median progression‐free survival (PFS) was 13.6 months in the adipopenic group and 49.4 months in the non‐adipopenic group [hazard ratio (HR) = 2.27; 95% confidence interval (CI): 1.3–4; P = 0.0042]. The median overall survival (OS) was 25.7 months in the adipopenic group and 57.1 months in the non‐adipopenic group (HR = 1.93; 95% CI: 1.05–3.55; P = 0.0342). A two‐point CS including adipopenia and sarcopenia was created and defined two distinct risk groups with differences in outcomes that were highly significant. The CS was predictive of the prognosis in a multivariate analysis including body mass index (BMI) (< or ≥25 kg/m2), age (< or ≥80 yr), international prognostic index (IPI) and albuminaemia (HR = 3.67; 95% CI = 1.93–6.97; P < 0.0001).ConclusionA CS including sarcopenia and adipopenia, assessed by a single CT scan slice, predicts outcome independent of BMI and the IPI.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Bone marrow transplantation · 2025 · Journal Article
Perruccio K, Ward KN, Tridello G, Knelange N, et al.
Acta haematologica · 2023 · Multicenter Study
Guisnel C, Schirmer L, Morisset S, Robin M, et al.
Haematologica · 2022 · Journal Article
Candon S, Lemee V, Leveque E, Etancelin P, et al.
Bone marrow transplantation · 2021 · Journal Article
Cornillon J, Daguenet E, Tournilhac O, Blaise D, et al.
Bone marrow transplantation · 2021 · Journal Article
Battipaglia G, Mauff K, Wendel L, Angelucci E, et al.
Bulletin du cancer · 2020 · Journal Article
Duléry R, Lacassagne MN, Giraud C, Ader V, et al.
Annals of hematology · 2019 · Journal Article
Cornillon J, Daguenet E, Bay JO, Chauchet A, et al.
Blood cancer journal · 2018 · Journal Article
Bohers E, Viailly PJ, Becker S, Marchand V, et al.
Cancer medicine · 2016 · Journal Article
Chevallier P, Labopin M, de La Tour RP, Lioure B, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016 · Journal Article
Guièze R, Damaj G, Pereira B, Robin M, et al.
American journal of respiratory and critical care medicine · 2015 · Journal Article
Bergeron A, Chevret S, Chagnon K, Godet C, et al.
Haematologica · 2013 · Journal Article
Marcais A, Porcher R, Robin M, Mohty M, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2010 · Comparative Study
Blache C, Chauvin JM, Marie-Cardine A, Contentin N, et al.
Clinical case reports · 2023 · Case Reports
Camus V, Etancelin P, Drieux F, Veresezan EL, et al.
Clinical case reports · 2021 · Case Reports
Krzisch D, Zduniak A, Veresezan EL, Daliphard S, et al.
JMM case reports · 2018 · Case Reports
Treguier P, David M, Gargala G, Camus V, et al.
Annals of hematology · 2024 · Published Erratum
Pénichoux J, Lanic H, Thill C, Ménard AL, et al.
Annals of hematology · 2023 · Journal Article
Pénichoux J, Lanic H, Thill C, Ménard AL, et al.
Clinical nutrition ESPEN · 2023 · Journal Article
Herault A, Lévêque E, Draye-Carbonnier S, Decazes P, et al.
JAMA · 2017 · Clinical Trial, Phase III
Bergeron A, Chevret S, Granata A, Chevallier P, et al.
Lancet (London, England) · 2012 · Clinical Trial, Phase III
Castaigne S, Pautas C, Terré C, Raffoux E, et al.
Annals of hematology · 2024 · Published Erratum
Pénichoux J, Lanic H, Thill C, Ménard AL, et al.
Annals of hematology · 2023 · Journal Article
Pénichoux J, Lanic H, Thill C, Ménard AL, et al.
European journal of haematology · 2014 · Journal Article
Camus V, Lanic H, Kraut J, Modzelewski R, et al.
American journal of hematology · 2025 · Journal Article
Esteve J, Nagler A, Labopin M, Versluis J, et al.
Fundamental & clinical pharmacology · 2021 · Journal Article
Belaiche S, Décaudin B, Caron A, Depas N, et al.
European journal of haematology · 2022 · Journal Article
Pénichoux J, Rio J, Kammoun L, Vermeulin T, et al.
Mycopathologia · 2015 · Journal Article
Loschi M, Thill C, Gray C, David M, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010 · Comparative Study
Pautas C, Merabet F, Thomas X, Raffoux E, et al.